Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics

Albert J. Robichaud, Darren W. Engers, Craig W. Lindsley, Corey R Hopkins

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

This Review describes recent activity in the advancement of ligands for the metabotropic glutamate 4 receptor subtype and their potential utility as central nervous system (CNS) therapeutics. Until recently, there was a paucity of compounds with suitable selectivity and druglike properties to elucidate the value of this target. The search for selective entities has led several groups to the investigation of allosteric modulators as a path to optimization of potential ligands. Recent efforts, discussed here, have afforded a variety of derivatives with improvements in potency, solubility, and pharmacokinetic properties that garner support for continued investigation and optimization.

Original languageEnglish (US)
Pages (from-to)433-449
Number of pages17
JournalACS Chemical Neuroscience
Volume2
Issue number8
DOIs
StatePublished - Aug 17 2011

Fingerprint

Neurology
Central Nervous System
Ligands
Pharmacokinetics
Solubility
Modulators
Derivatives
Therapeutics
metabotropic glutamate receptor 4

Keywords

  • Class C GPCR
  • Metabotropic glutamate receptor 4
  • Parkinson's disease
  • allosteric modulator
  • anxiety
  • cognitive disorders
  • neurodegenerative disorders
  • orthosteric ligand
  • pain
  • psychiatric disorders

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics. / Robichaud, Albert J.; Engers, Darren W.; Lindsley, Craig W.; Hopkins, Corey R.

In: ACS Chemical Neuroscience, Vol. 2, No. 8, 17.08.2011, p. 433-449.

Research output: Contribution to journalReview article

@article{db36bb4ffec14524ab0d856b641b1598,
title = "Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics",
abstract = "This Review describes recent activity in the advancement of ligands for the metabotropic glutamate 4 receptor subtype and their potential utility as central nervous system (CNS) therapeutics. Until recently, there was a paucity of compounds with suitable selectivity and druglike properties to elucidate the value of this target. The search for selective entities has led several groups to the investigation of allosteric modulators as a path to optimization of potential ligands. Recent efforts, discussed here, have afforded a variety of derivatives with improvements in potency, solubility, and pharmacokinetic properties that garner support for continued investigation and optimization.",
keywords = "Class C GPCR, Metabotropic glutamate receptor 4, Parkinson's disease, allosteric modulator, anxiety, cognitive disorders, neurodegenerative disorders, orthosteric ligand, pain, psychiatric disorders",
author = "Robichaud, {Albert J.} and Engers, {Darren W.} and Lindsley, {Craig W.} and Hopkins, {Corey R}",
year = "2011",
month = "8",
day = "17",
doi = "10.1021/cn200043e",
language = "English (US)",
volume = "2",
pages = "433--449",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "8",

}

TY - JOUR

T1 - Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics

AU - Robichaud, Albert J.

AU - Engers, Darren W.

AU - Lindsley, Craig W.

AU - Hopkins, Corey R

PY - 2011/8/17

Y1 - 2011/8/17

N2 - This Review describes recent activity in the advancement of ligands for the metabotropic glutamate 4 receptor subtype and their potential utility as central nervous system (CNS) therapeutics. Until recently, there was a paucity of compounds with suitable selectivity and druglike properties to elucidate the value of this target. The search for selective entities has led several groups to the investigation of allosteric modulators as a path to optimization of potential ligands. Recent efforts, discussed here, have afforded a variety of derivatives with improvements in potency, solubility, and pharmacokinetic properties that garner support for continued investigation and optimization.

AB - This Review describes recent activity in the advancement of ligands for the metabotropic glutamate 4 receptor subtype and their potential utility as central nervous system (CNS) therapeutics. Until recently, there was a paucity of compounds with suitable selectivity and druglike properties to elucidate the value of this target. The search for selective entities has led several groups to the investigation of allosteric modulators as a path to optimization of potential ligands. Recent efforts, discussed here, have afforded a variety of derivatives with improvements in potency, solubility, and pharmacokinetic properties that garner support for continued investigation and optimization.

KW - Class C GPCR

KW - Metabotropic glutamate receptor 4

KW - Parkinson's disease

KW - allosteric modulator

KW - anxiety

KW - cognitive disorders

KW - neurodegenerative disorders

KW - orthosteric ligand

KW - pain

KW - psychiatric disorders

UR - http://www.scopus.com/inward/record.url?scp=80051716135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051716135&partnerID=8YFLogxK

U2 - 10.1021/cn200043e

DO - 10.1021/cn200043e

M3 - Review article

VL - 2

SP - 433

EP - 449

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 8

ER -